News & insights
Date: January 2020 | Client: Unitaid | Sector: Global health | Epidemics and communicable diseases | Expertise: Health economics & evaluation
Unitaid long-acting HIV drugs modelling support
Unitaid commissioned CEPA to develop a model to quantify the potential uptake and impact of long-acting drugs for anti-retroviral treatment of HIV. The aim was to explore dependencies around the role which different long-acting formulations in development could play in the global HIV response. The model was presented to stakeholders including WHO, Global Fund, the Medicines Patent Pool, the Clinton Health Access Initiative and Unitaid grantees at session of Unitaid’s Long-Acting Project Advisory Group.
To find out more, please contact our experts listed below.
